{
    "root": "6d23c13f-f81d-4bc9-9ded-be94c025e8f7",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "IVABRADINE",
    "value": "20250221",
    "ingredients": [
        {
            "name": "IVABRADINE HYDROCHLORIDE",
            "code": "TP19837BZK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_85969"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MALTODEXTRIN",
            "code": "7CVR7L4A2D",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25140"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "POLYETHYLENE GLYCOL 4000",
            "code": "4R4HFI6D95",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "indications": {
        "text": "ivabradine hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated : reduce risk hospitalization worsening heart failure adult patients stable , symptomatic chronic heart failure reduced left ventricular ejection fraction . ( 1.1 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "chronic heart failure",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_294422"
            }
        ]
    },
    "contraindications": {
        "text": "adult patients \u25cf starting dose 2.5 ( vulnerable adults ) 5 mg twice daily food . 2 weeks treatment , adjust dose based heart rate . maximum dose 7.5 mg twice daily . ( 2.1 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "ivabradine tablets 5 mg tablets formulated light salmon-colored , capsule-shaped , film-coated scored tablets debossed `` i5 `` divided score one side plain . supplied follows : bottles 60 tablets child-resistant closure , ( ndc 50742-362-60 ) bottles 180 tablets child-resistant closure , ( ndc 50742-362-18 ) ivabradine tablets 7.5 mg tablets formulated light salmon-colored , round-shaped , film-coated tablets debossed `` `` one side `` 7.5 `` side . supplied follows : bottles 60 tablets child-resistant closure , ( ndc 50742-363-60 ) bottles 180 tablets child-resistant closure , ( ndc 50742-363-18 ) storage store ivabradine tablets 25\u00bac ( 77\u00baf ) ; excursions permitted 15\u00bac - 30\u00bac ( 59\u00baf -86\u00baf ) [ usp controlled room temperature ] .",
    "adverseReactions": "ivabradine tablets contraindicated patients : acute decompensated heart failure clinically significant hypotension sick sinus syndrome , sinoatrial block 3rddegree av block , unless functioning demand pacemaker present clinically significant bradycardia [ ( 5.3 ) ] severe hepatic impairment [ ( 8.6 ) ] pacemaker dependence ( heart rate maintained exclusively pacemaker ) [ ( 7.3 ) ] concomitant strong cytochrome p450 3a4 ( cyp3a4 ) inhibitors [ ( 7.1 ) ]",
    "indications_original": "Ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 )",
    "contraindications_original": "Adult patients \u25cf\u00a0\u00a0\u00a0\u00a0 Starting dose is 2.5 (vulnerable adults) or 5 mg twice daily with food. After 2 weeks of treatment, adjust dose based on heart rate. The maximum dose is 7.5 mg twice daily. ( 2.1 )",
    "warningsAndPrecautions_original": "Ivabradine tablets 5 mg tablets are formulated as Light salmon-colored, Capsule-shaped, film-coated scored tablets debossed with \"I5\" divided by the score on one side and plain on the other. \n                  They are supplied as follows:\n                  \n                     Bottles of 60 tablets with child-resistant closure, (NDC 50742-362-60)\n                     Bottles of 180 tablets with child-resistant closure, (NDC 50742-362-18)\n                  \n                  Ivabradine tablets 7.5 mg tablets are formulated as Light salmon-colored, Round-shaped, film-coated tablets debossed with \"I\" on one side and \"7.5\" on the other side. They are supplied as follows:\n                  \n                     Bottles of 60 tablets with child-resistant closure, (NDC 50742-363-60)\n                     Bottles of 180 tablets with child-resistant closure, (NDC 50742-363-18)\n                  \n                  \n                     Storage\n                  \n                  Store ivabradine tablets at 25\u00baC (77\u00baF); excursions permitted to 15\u00baC - 30\u00baC (59\u00baF -86\u00baF) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Ivabradine tablets are contraindicated in patients with:\n                  \n                     Acute decompensated heart failure\n                     Clinically significant hypotension\n                     Sick sinus syndrome, sinoatrial block or 3rddegree AV block, unless a functioning demand pacemaker is present\n                     Clinically significant bradycardia [see Warnings and Precautions (5.3)]\n                     \n                     Severe hepatic impairment [see Use in Specific Populations (8.6)]\n                     \n                     Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions (7.3)]\n                     \n                     Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions (7.1)]",
    "drug": [
        {
            "name": "IVABRADINE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_85966"
        }
    ]
}